The Digital Therapeutics Alliance, in collaboration with DirectTrust, is gearing up to introduce an accreditation program tailored for digital therapeutics products. This strategic move comes in response to payer reluctance, notably from entities like the Centers for Medicare and Medicaid Services (CMS), stemming from the fallout of key DTx companies such as Pear Therapeutics experiencing bankruptcy last year.
Andy Molnar, CEO of the Digital Therapeutics Alliance, made this announcement during the organization's annual conference, stressing the imperative of establishing stringent efficacy evaluation criteria to foster trust within the industry. DirectTrust, renowned for its proficiency in privacy, security, and interoperability standards, will join forces with DTA to implement this accreditation initiative, thus broadening its array of assessment programs tailored for the dynamic digital health app and platform market. Molnar emphasized that the accreditation process will be comprehensive and collaborative, with a particular emphasis on formulating efficacy criteria specific to DTx products. Currently, DTA is in the process of recruiting members for the DirectTrust Criteria Council Sub-Group, tasked with aiding in this crucial endeavor.
Click here to read the original news story.